SCHEMBL3149189

SCHEMBL3149189

NCCCNC(=O)C(F)(F)F

nearest known ligand 0.74

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.74
SMN1; SMN2 Q16637 2/20 0.74
POLB P06746 1/20 0.74
MEN1 O00255 1/20 0.71
KMT2A Q03164 1/20 0.71
CA3 P07451 2/20 0.63
CA5A P35218 2/20 0.63
CA5B Q9Y2D0 2/20 0.63
CA14 Q9ULX7 2/20 0.63
CA2 P00918 2/20 0.63
CA12 O43570 1/20 0.63
CA4 P22748 1/20 0.63
CA6 P23280 1/20 0.63
CA7 P43166 1/20 0.63
CA9 Q16790 1/20 0.63
EPHX1 P07099 1/20 0.59
HDAC6 Q9UBN7 1/20 0.48
PAOX Q6QHF9 3/20 0.43
GLA P06280 1/20 0.42
HPGD P15428 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL29241548 0.98 SMN1; SMN2 (0.71) ALDH1A1SMN1; SMN2POLBMEN1KMT2A
SCHEMBL6490885 0.93 ALDH1A1 (0.78) ALDH1A1SMN1; SMN2POLBMEN1KMT2A
SCHEMBL19781069 0.91 MEN1 (0.79) ALDH1A1SMN1; SMN2POLBMEN1KMT2A
Hydrochloric Acid SCHEMBL29241679 0.91 SMN1; SMN2 (0.75) ALDH1A1SMN1; SMN2POLBMEN1KMT2A
SCHEMBL5367616 0.91 MEN1 (0.79) ALDH1A1SMN1; SMN2POLBMEN1KMT2A
SCHEMBL3302767 0.90 CA5A (0.81) ALDH1A1SMN1; SMN2POLBMEN1KMT2A
Hydrochloric Acid SCHEMBL28974271 0.90 MEN1 (0.76) ALDH1A1SMN1; SMN2POLBMEN1KMT2A
SCHEMBL7701423 0.89 ALDH1A1 (0.59) ALDH1A1SMN1; SMN2POLBMEN1KMT2A
Hydrochloric Acid SCHEMBL7705195 0.87 ALDH1A1 (0.57) ALDH1A1SMN1; SMN2POLBMEN1KMT2A
Trifluoroacetic Acid SCHEMBL30387588 0.86 MEN1 (0.70) ALDH1A1SMN1; SMN2POLBMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2670750-B1 NAPHTHYRIDINE DERIVATIVES AS INHIBITORS OF HYPOXIA INDUCIBLE FACTOR FIBROGEN INC (US) 2016-09-14 EP claimed
US-9271970-B2 Naphthyridine derivatives as inhibitors of hypoxia inducible factor (HIF) hydroxylase FIBROGEN, INC. (US) 2016-03-01 US claimed
US-20150174110-A1 NAPHTHYRIDINE DERIVATIVES AS INHIBITORS OF HYPOXIA INDUCIBLE FACTOR (HIF) HYDROXYLASE FIBROGEN, INC. 2015-06-25 US claimed
US-8921389-B2 Naphthyridine derivatives as inhibitors of hypoxia inducible factor (HIF) hydroxylase FIBROGEN, INC. (US) 2014-12-30 US claimed
US-20140088101-A1 NAPHTHYRIDINE DERIVATIVES AS INHIBITORS OF HYPOXIA INDUCIBLE FACTOR (HIF) HYDROXYLASE FIBROGEN, INC. (US) 2014-03-27 US claimed
EP-2670750-A1 NAPHTHYRIDINE DERIVATIVES AS INHIBITORS OF HYPOXIA INDUCIBLE FACTOR (HIF) HYDROXYLASE Fibrogen, Inc. (US) 2013-12-11 EP claimed
WO-2012106472-A1 NAPHTHYRIDINE DERIVATIVES AS INHIBITORS OF HYPOXIA INDUCIBLE FACTOR (HIF) HYDROXYLASE FIBROGEN, INC. (US) 2012-08-09 WO claimed
US-20230210999-A1 TARGETED PROTEASE DEGRADATION (TED) PLATFORM EUBULUS BIOTHERAPEUTICS (HONG KONG) LIMITED (HK) 2023-07-06 US disclosed
US-20230210999-A1 TARGETED PROTEASE DEGRADATION (TED) PLATFORM EUBULUS BIOTHERAPEUTICS (HONG KONG) LIMITED (HK) 2023-07-06 US disclosed
EP-4134104-A1 TARGETED PROTEASE DEGRADATION (TED) PLATFORM Eubulus Biotherapeutics Inc. (CN) 2023-02-15 EP disclosed
EP-3971166-A1 MOLECULES HAVING PESTICIDAL UTILITY, AND COMPOSITIONS, AND PROCESSES, RELATED THERETO Corteva Agriscience LLC (US) 2022-03-23 EP disclosed
US-20210161144-A1 MOLECULES HAVING PESTICIDAL UTILITY, AND INTERMEDIATES, COMPOSITIONS, AND PROCESSES, RELATED THERETO DOW AGROSCIENCES LLC (US) 2021-06-03 US disclosed
US-10993440-B2 Molecules having pesticidal utility, and intermediates, compositions, and processes related thereto DOW AGROSCIENCES LLC (US) 2021-05-04 US disclosed
EP-2012759-A1 PURINE DERIVATIVES AS A2A RECEPTOR AGONISTS Novartis AG (CH) 2009-01-14 EP disclosed
EP-1841768-B1 PURINE DERIVATIVES ACTING AS A2A RECEPTOR AGONISTS NOVARTIS AG (CH) 2008-11-12 EP disclosed
US-20080207648-A1 Organic Compounds NOVARTIS AG (CH) 2008-08-28 US disclosed
WO-2007121923-A1 PURINE DERIVATIVES AS A2A RECEPTOR AGONISTS NOVARTIS AG (CH) 2007-11-01 WO disclosed
EP-1841768-A1 PURINE DERIVATIVES ACTING AS A2A RECEPTOR AGONISTS Novartis AG (CH) 2007-10-10 EP disclosed
WO-2007084498-A1 PIPERAZINE DERIVATIVES AS FARNESYL PROTEIN TRANSFERASE INHIBITORS SCHERING CORPORATION (US) 2007-07-26 WO disclosed
WO-2006074925-A1 PURINE DERIVATIVES ACTING AS A2A RECEPTOR AGONISTS NOVARTIS AG (CH) 2006-07-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150174110-A1 NAPHTHYRIDINE DERIVATIVES AS INHIBITORS OF HYPOXIA INDUCIBLE FACTOR (HIF) HYDROXYLASE HIF1AN, HIF1A, EGLN2 ALDH1A1 660/4885SMN1; SMN2 4317/4885POLB 496/4885
US-20230210999-A1 TARGETED PROTEASE DEGRADATION (TED) PLATFORM UCHL3, UBE2L3, ADAM33 ALDH1A1 2539/4885SMN1; SMN2 2462/4885POLB 4028/4885
US-10993440-B2 Molecules having pesticidal utility, and intermediates, compositions, and processes related thereto ACHE, DDT, MLYCD ALDH1A1 386/4885SMN1; SMN2 3694/4885POLB 3689/4885
US-20140088101-A1 NAPHTHYRIDINE DERIVATIVES AS INHIBITORS OF HYPOXIA INDUCIBLE FACTOR (HIF) HYDROXYLASE HIF1AN, HIF1A, EGLN2 ALDH1A1 660/4885SMN1; SMN2 4317/4885POLB 496/4885
US-20210161144-A1 MOLECULES HAVING PESTICIDAL UTILITY, AND INTERMEDIATES, COMPOSITIONS, AND PROCESSES, RELATED THERETO ACHE, DDT, MLYCD ALDH1A1 443/4885SMN1; SMN2 3645/4885POLB 3630/4885
US-20080207648-A1 Organic Compounds ADORA2A, ADORA1, ADORA3 ALDH1A1 201/4885SMN1; SMN2 3845/4885POLB 2576/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.